U.S. Anti-obesity Drugs MarketU.S. Anti-obesity Drugs Market 26.5 CAGR Growth Outlook 2024-2030
U.S. Anti-obesity Drugs Market by Type (Prescription Drugs, Over-the-counter (OTC), by Distribution Channel (Hospital Pharmacy, Retail, Online Pharmacy), by Forecast 2024-2032
Base Year: 2023
180 Pages
U.S. Anti-obesity Drugs Market 26.5 CAGR Growth Outlook 2024-2030
Key Insights
The U.S. Anti-obesity Drugs Market size was valued at USD 1.71 USD Billion in 2023 and is projected to reach USD 8.86 USD Billion by 2032, exhibiting a CAGR of 26.5 % during the forecast period. Anti-obesity drugs are medications that were created to facilitate the weight-loss process that is based on suppressing appetite, consuming less metabolism, or absorption of nutrients. They are a very diverse class having appetite suppressors, lipase inhibitors, and serotonin-norepinephrine reuptake inhibitors (SNRIs) as members. Such medications interfere with neural networks or hormones that are often linked to the control of hunger and satiety. In the US, there becomes an application of intermittent fasting as an auxiliary to weight loss regimens is one of the strategies to fight obesity and furthermore, metabolic disorders such as type 2 diabetes. Recent market indices are showing a trend that is inclined towards safe and effective anti-obesity drugs with lesser or no side effects which in turn is creating momentum for research on new ways and formulations to fight obesity and the ever-growing health crisis.
U.S. Anti-Obesity Drugs Trends
- Increasing demand for prescription drugs with proven efficacy and safety
- Growing popularity of over-the-counter weight loss supplements
- Shift towards telehealth and online pharmacy for convenience and accessibility
Driving Forces: What's Propelling the U.S. Anti-Obesity Drugs Market
- Surge in obesity rates due to factors such as unhealthy diets and sedentary lifestyles
- Government initiatives to combat obesity and promote healthy weight management
- Advances in drug development, led to the availability of more effective and tolerable therapies
- Growing awareness of the health risks associated with obesity, including cardiovascular disease, type 2 diabetes, and cancer
Challenges and Restraints in U.S. Anti-Obesity Drugs Market
- Insurance coverage limitations for weight loss treatments
- Potential side effects and safety concerns associated with certain drugs
- Lack of long-term efficacy and sustainability of weight loss results
- Stringent regulatory requirements for drug approval
Emerging Trends in U.S. Anti-Obesity Drugs
- Personalized medicine approaches based on genetic and metabolic profiles
- Combination therapies utilizing multiple drugs to enhance efficacy and reduce side effects
- Digital health solutions for weight loss management, including mobile apps and wearable devices
Growth Catalysts in U.S. Anti-Obesity Drugs Industry
- Investment in research and development of novel therapies
- Government funding for obesity prevention and treatment programs
- Collaboration between healthcare providers, pharmaceutical companies, and research institutions
Market Segmentation: U.S. Anti-Obesity Drugs Analysis
Type:
- Prescription Drugs
- GLP-1 Agonists
- Phentermine and Topiramate
- Lorcaserin
- Naltrexone and Bupropion
- Over-the-counter (OTC)
Distribution Channel:
- Hospital Pharmacy
- Retail and Online Pharmacy
Leading Players in the U.S. Anti-Obesity Drugs Market
- Novo Nordisk A/S
- GSK plc
- VIVUS LLC
- Currax Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sandoz International GmbH (Novartis AG)
- Boehringer Ingelheim International GmbH
Significant Developments in U.S. Anti-Obesity Drugs Sector
- July 2023: Capital Rx partners with Virta Health to launch Rx Reverse, an integrated clinical program for GLP-1 drugs.
- May 2023: Noom launches a telehealth program offering Wegovy and weight loss services.
- December 2022: Amgen Inc. announces positive phase I clinical trial results for AMG 133, demonstrating a 14.5% body weight reduction.
Comprehensive Coverage U.S. Anti-Obesity Drugs Market Report
The report covers the following aspects:
- Detailed market analysis and industry forecasts
- Comprehensive SWOT analysis
- Key market trends and drivers
- Segmentation by type, distribution channel, region
- Regulatory landscape and pricing analysis
- Profiles of leading market players and their strategies
U.S. Anti-obesity Drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 26.5% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Technological Developments in Products to Propel Market Growth
- 3.3. Market Restrains
- 3.3.1. Stringent Regulatory Process May Limit the Market Growth
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Prescription Drugs
- 5.1.2. Over-the-counter (OTC
- 5.2. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.2.1. Hospital Pharmacy
- 5.2.2. Retail
- 5.2.3. Online Pharmacy
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1.
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. Northeast U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Prescription Drugs and Over-the-counter (OTC
- 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.2.1. Hospital Pharmacy and Retail and Online Pharmacy
- 7. Southeast U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Prescription Drugs and Over-the-counter (OTC
- 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.2.1. Hospital Pharmacy and Retail and Online Pharmacy
- 8. Midwest U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Prescription Drugs and Over-the-counter (OTC
- 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.2.1. Hospital Pharmacy and Retail and Online Pharmacy
- 9. Southwest U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Prescription Drugs and Over-the-counter (OTC
- 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.2.1. Hospital Pharmacy and Retail and Online Pharmacy
- 10. West U.S. Anti-obesity Drugs Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Prescription Drugs and Over-the-counter (OTC
- 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.2.1. Hospital Pharmacy and Retail and Online Pharmacy
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 Novo Nordisk A/S (Denmark)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 GSK plc (U.K.)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 VIVUS LLC. (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Currax Pharmaceuticals LLC (U.S.)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 F. Hoffmann-La Roche Ltd (Switzerland)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Pfizer Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Sandoz International GmbH (Novartis AG) (Germany)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Boehringer Ingelheim International GmbH (Germany)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.1 Novo Nordisk A/S (Denmark)
List of Figures
- Figure 1: U.S. Anti-obesity Drugs Market Revenue Breakdown (USD Billion, %) by Product 2023 & 2031
- Figure 2: U.S. Anti-obesity Drugs Market Value Share (%), by Type 2023 & 2031
- Figure 3: U.S. Anti-obesity Drugs Market Value Share (%), by Distribution Channel 2023 & 2031
- Figure 4: U.S. Anti-obesity Drugs Market Share (%) by Company 2023
List of Tables
- Table 1: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 2: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2018 & 2031
- Table 3: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 4: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2018 & 2031
- Table 5: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 6: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Region 2018 & 2031
- Table 7: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 8: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2018 & 2031
- Table 9: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 10: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2018 & 2031
- Table 11: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Region 2018 & 2031
- Table 12: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Region 2018 & 2031
- Table 13: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 14: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2018 & 2031
- Table 15: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 16: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2018 & 2031
- Table 17: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 18: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Country 2018 & 2031
- Table 19: Northeast U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 20: Northeast U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2018 & 2031
- Table 21: Southeast U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 22: Southeast U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2018 & 2031
- Table 23: Midwest U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 24: Midwest U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2018 & 2031
- Table 25: Southwest U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 26: Southwest U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2018 & 2031
- Table 27: West U.S. Anti-obesity Drugs Market Revenue (USD Billion) Forecast, by Application 2018 & 2031
- Table 28: West U.S. Anti-obesity Drugs Market Volume (K Units) Forecast, by Application 2018 & 2031
- Table 29: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Type 2018 & 2031
- Table 30: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Type 2018 & 2031
- Table 31: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Distribution Channel 2018 & 2031
- Table 32: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Distribution Channel 2018 & 2031
- Table 33: U.S. Anti-obesity Drugs Market Revenue USD Billion Forecast, by Country 2018 & 2031
- Table 34: U.S. Anti-obesity Drugs Market Volume K Units Forecast, by Country 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 26.5% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
